Cargando…
Japanese Expert Panel Meeting on the Management of Prostate Cancer with Bone Metastases
INTRODUCTION: The incidence of prostate cancer in Japan continues to increase, necessitating the continued development of effective therapies and strategies. Recent advances in treatments have improved the prognosis of metastatic disease and highlighted the importance of treating bone metastases to...
Autores principales: | Takahashi, Shunji, Kinuya, Seigo, Nonomura, Norio, Shinohara, Nobuo, Suzuki, Kazuhiro, Suzuki, Hiroyoshi, Nakamura, Katsumasa, Satoh, Takefumi, Tateishi, Ukihide, Yoneda, Toshiyuki, Horikoshi, Hiroyuki, Igawa, Tsukasa, Kamai, Takao, Koizumi, Mitsuru, Kosaka, Takeo, Matsubara, Nobuaki, Miyake, Hideaki, Mizokami, Atsushi, Mizowaki, Takashi, Nakamura, Naoki, Nozawa, Masahiro, Takahashi, Takeo, Uemura, Hiroji, Uemura, Motohide, Yokomizo, Akira, Yoshimura, Mana, Kakehi, Yoshiyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359992/ https://www.ncbi.nlm.nih.gov/pubmed/32700033 http://dx.doi.org/10.1007/s40487-018-0088-0 |
Ejemplares similares
-
Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2017) -
Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases
por: Uemura, Hirotsugu, et al.
Publicado: (2019) -
Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
por: Uemura, Hiroji, et al.
Publicado: (2017) -
Real-world safety and effectiveness of radium-223 in Japanese patients with castration-resistant prostate cancer (CRPC) and bone metastasis: exploratory analysis, based on the results of post-marketing surveillance, according to prior chemotherapy status and in patients without concomitant use of second-generation androgen-receptor axis-targeted agents
por: Uemura, Hirotsugu, et al.
Publicado: (2021) -
Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration‐resistant prostate cancer: AFTERCAB study
por: Uemura, Hiroji, et al.
Publicado: (2021)